Filip Roudnicky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1032000/publications.pdf

Version: 2024-02-01

623734 677142 1,176 21 14 22 citations g-index h-index papers 23 23 23 2591 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Preventing VEGF-Mediated Vascular Permeability by Experimentally Potentiating BBB Characteristics in Endothelial Cells. Methods in Molecular Biology, 2022, 2475, 259-274.	0.9	O
2	Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19854-19865.	7.1	35
3	Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis. Cell Stem Cell, 2020, 27, 147-157.e7.	11.1	17
4	Identification of a combination of transcription factors that synergistically increases endothelial cell barrier resistance. Scientific Reports, 2020, 10, 3886.	3. 3	40
5	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. American Journal of Pathology, 2020, 190, 1960-1970.	3.8	8
6	Functional Genomics for Cancer Drug Target Discovery. Cancer Cell, 2020, 38, 31-43.	16.8	46
7	Monolayer Generation of Vascular Endothelial Cells from Human Pluripotent Stem Cells. Methods in Molecular Biology, 2019, 1994, 17-29.	0.9	8
8	Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. ACS Chemical Biology, 2019, 14, 2215-2223.	3.4	74
9	Modeling the Effects of Severe Metabolic Disease by Genome Editing of hPSC-Derived Endothelial Cells Reveals an Inflammatory Phenotype. International Journal of Molecular Sciences, 2019, 20, 6201.	4.1	3
10	Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels. Oncogene, 2018, 37, 2573-2585.	5. 9	22
11	High expression of insulin receptor on tumourâ€associated blood vessels in invasive bladder cancer predicts poor overall and progressionâ€free survival. Journal of Pathology, 2017, 242, 193-205.	4.5	24
12	Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery. Advances in Biochemical Engineering/Biotechnology, 2017, 163, 207-220.	1.1	7
13	An integrated expression atlas of miRNAs and their promoters in human and mouse. Nature Biotechnology, 2017, 35, 872-878.	17.5	456
14	Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics Data, 2016, 8, 1-3.	1.3	5
15	CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Disease Markers, 2015, 2015, 1-8.	1.3	34
16	Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports, 2015, 5, 9188.	3.3	119
17	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	2.0	34
18	Steering Target Selectivity and Potency by Fragmentâ€Based De Novo Drug Design. Angewandte Chemie - International Edition, 2013, 52, 10006-10009.	13.8	23

FILIP ROUDNICKY

#	Article	IF	CITATIONS
19	De novo design and optimization of Aurora A kinase inhibitors. Chemical Science, 2013, 4, 1229.	7.4	23
20	Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis. Cancer Research, 2013, 73, 1097-1106.	0.9	150
21	Inflammation-Induced Lymph Node Lymphangiogenesis Is Reversible. American Journal of Pathology, 2012, 180, 874-879.	3.8	32